Negative psychosis prevention trials

JAMA Psychiatry

Volumn 74, Issue 6, 2017, Pages 651-

  Fusar Poli, Paolo ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OMEGA 3 FATTY ACID; NEUROLEPTIC AGENT;

CLINICAL TRIAL (TOPIC); HIGH RISK POPULATION; HUMAN; LETTER; PSYCHOMETRY; PSYCHOSIS; RISK ASSESSMENT; TREATMENT OUTCOME; ADOLESCENT;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; FATTY ACIDS, OMEGA-3; HUMANS; PSYCHOTIC DISORDERS;

EID: 85020748551     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2017.0185     Document Type: Letter

References (5)

1. McGorry P, Nelson B, Markulev C, et al. Effect of-3 polyunsaturated fatty acids in young people at ultrahigh risk for psychotic disorders: The NEURAPRO randomized clinical trial. JAMA Psychiatry. 2017;74(1):19-27.
2. Morrison AP, French P, Stewart SL, et al. Early detection and intervention evaluation for people at risk of psychosis: Multisite randomised controlled trial. BMJ. 2012;344:e2233.
3. McFarlane WR, Levin B, Travis L, et al. Clinical and functional outcomes after 2 years in the early detection and intervention for the prevention of psychosis multisite effectiveness trial. Schizophr Bull. 2015;41(1):30-43.
4. Fusar-Poli P, Schultze-Lutter F, Cappucciati M, et al. The dark side of the moon: Meta-analytical impact of recruitment strategies on risk enrichment in the clinical high risk state for psychosis. Schizophr Bull. 2016;42(3):732-743.
5. Fusar-Poli P, Rutigliano G, Stahl D, et al. Deconstructing pretest risk enrichment to optimize prediction of psychosis in individuals at clinical high risk. JAMA Psychiatry. 2016;73(12):1260-1267.